Biotie Therapies - Company Announcement

Biotie Commences Proposed U.S. Public Offering of ADSs

BIOTIE THERAPIES CORP.       STOCK EXCHANGE RELEASE  June 4, 2015 at 3.50 p.m.

Biotie Commences Proposed U.S. Public Offering of ADSs

Biotie Therapies Oyj, a specialized drug development company focused on products
for neurodegenerative and psychiatric disorders, has today commenced the
marketing of a proposed U.S. public offering of $50 million American Depositary
Shares ("ADSs") representing its shares, based on the authorization granted by
the Annual General Meeting of shareholders on May 26, 2015.

On June 2, 2015, the last reported sale price of Biotie's shares on the NASDAQ
OMX Helsinki Ltd. was €0.168 per share, which is equivalent to a price of $14.82
per ADS, assuming an exchange rate of $1.1029 per euro and a share to ADS ratio
of 80 to one. Based on these prices and assumptions, a total of 3,373,142 ADSs
would be offered, representing 269,851,344 newly issued shares. Biotie's shares
are listed on the NASDAQ OMX Helsinki Ltd. under the symbol "BTH1V."An
application has been made to list the ADSs on the NASDAQ Global Market under the
symbol "BITI."  The offering is expected to be completed by the end of June.

Biotie also intends to grant the underwriters a 30-day option to subscribe for
up to an additional 15% of the shares represented by ADSs sold in the U.S.
public offering for the sole purpose of covering potential over-allotments.

As previously announced, Biotie intends to use the net proceeds from the
offering, together with a portion of its current liquid assets (which include
€33.1 million gross proceeds from its recent private financing) to fund its
Phase 3 double-blind clinical trial (and extension) of tozadenant in Parkinson's
through completion.

Certain of Biotie's existing investors and certain members of its board of
directors have indicated an interest in purchasing up to an aggregate of $25
million of ADSs in the U.S. public offering at the public offering price.
However, because indications of interest are not binding agreements or
commitments to purchase, these entities and persons may determine to not
purchase any ADSs in the offering. It is also possible that these entities and
persons and additional existing investors could indicate an interest in
purchasing more of the ADSs. In addition, the underwriters could determine to
sell fewer ADSs to any of these entities or persons than such entities or
persons indicate an interest in purchasing or to not sell any ADSs to these
entities and persons.

RBC Capital Markets and Stifel are acting as joint book-running managers in
connection with the offering. In addition, JMP Securities is acting as lead
manager and Roth Capital Partners is acting as co-manager.

A registration statement relating to the securities to be issued in the offering
has been filed with the U.S. Securities and Exchange Commission but has not yet
become effective. These securities may not be sold, nor may offers to buy be
accepted, prior to the time the registration statement becomes effective.

The securities to be issued in the offering are to be offered only by means of a
prospectus. Copies of the preliminary prospectus related to the offering may be
obtained from: RBC Capital Markets, LLC, 200 Vesey Street, 8th Floor, New York,
New York 10281, Attention: Equity Syndicate Department, or by calling
+1 877 822 4089, or by emailing equityprospectus@rbccm.com, or from Stifel,
Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street,
Suite 3700, San Francisco, California 94104, by telephone at +1 415 364 2720 or
by email at syndprospectus@stifel.com.

This stock exchange release does not constitute an offer to sell nor a
solicitation of an offer to buy, nor shall there be any sale of securities in
any state or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of any
such state or jurisdiction.

Turku, June 4, 2015

Biotie Therapies Corp.

Timo Veromaa
President and CEO



Contact:

Virve Nurmi, Investor Relations Manager, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com

DISTRIBUTION:
NASDAQ OMX Helsinki Ltd
Main Media

About Biotie

Biotie is a specialized drug development company focused on products for
neurodegenerative and psychiatric disorders. Biotie's development has delivered
Selincro (nalmefene) for alcohol dependence, which received European marketing
authorization in 2013 and is currently being rolled out across Europe by partner
Lundbeck. The current development products include tozadenant for Parkinson's
disease, which is transitioning into Phase 3 development, and two additional
compounds which are in Phase 2 development for cognitive disorders including
Parkinson's disease dementia, and primary sclerosing cholangitis (PSC), a rare
fibrotic disease of the liver.

Disclaimer

The information herein may not be distributed or sent into Australia, Canada,
Japan or South Africa.

The issue, exercise and/or sale of securities in the offerings are subject to
specific legal or regulatory restrictions in certain jurisdictions. The Company
assumes no responsibility in the event there is a violation by any person of
such restrictions. Investors must neither accept any offer for, nor acquire, any
securities to which this document refers, unless they do so on the basis of the
information contained in the applicable prospectus published or offering
circular distributed by the Company.

The Company has not authorized any offer to the public of securities in any
Member State of the European Economic Area, including Finland. With respect to
each Member State of the European Economic Area, including Finland, which has
implemented the Prospectus Directive (each, a "Relevant Member State"), no
action has been undertaken or will be undertaken to make an offer to the public
of securities requiring publication of a prospectus in any Relevant Member
State. As a result, the securities may only be offered in Relevant Member States
(a) to any legal entity which is a qualified investor as defined in the
Prospectus Directive; or (b) in any other circumstances falling within Article
3(2) of the Prospectus Directive. For the purposes of this paragraph, the
expression an "offer of securities to the public" means the communication in any
form and by any means of sufficient information on the terms of the offer and
the securities to be offered so as to enable an investor to decide to exercise,
purchase or subscribe the securities, as the same may be varied in that Member
State by any measure implementing the Prospectus Directive in that Member State
and the expression "Prospectus Directive" means Directive 2003/71/EC (and
amendments thereto, including the 2010 PD Amending Directive, to the extent
implemented in the Relevant Member State), and includes any relevant
implementing measure in the Relevant Member State and the expression "2010 PD
Amending Directive" means Directive 2010/73/EU.

This communication is directed only at (i) persons who are outside the United
Kingdom or (ii) persons who have professional experience in matters relating to
investments falling within Article 19(5) of the Financial Services and Markets
Act 2000 (Financial Promotion) Order 2005 (the "Order") and (iii) high net worth
entities, and other persons to whom it may lawfully be communicated, falling
within Article 49(2) of the Order (all such persons together being referred to
as "relevant persons"). Any investment activity to which this communication
relates will only be available to and will only be engaged with, relevant
persons. Any person who is not a relevant person should not act or rely on this
document or any of its contents.

Forward-Looking Statements

This release may contain forward-looking statements regarding the proposed
timing and size of the public offering, all of which involve certain risks and
uncertainties. These statements are often, but are not always, made through the
use of words or phrases such as "believes,""anticipates,""expects,""intends,""plans,""seeks,""estimates,""may,""will,""could,""stands to,""continues,""we believe,""we intend," as well as similar expressions. Such forward-looking
statements may involve known and unknown risks, uncertainties and other factors
which might cause the actual results, financial condition, performance or
achievements of Biotie, or industry results, to be materially different from any
historic or future results, financial conditions, performance or achievements
expressed or implied by such forward-looking statements. Among the factors that
may result in differences are the inherent uncertainties associated with
competitive developments, clinical trial and product development activities,
regulatory approval requirements and estimating the commercial potential of our
product candidates. Given these uncertainties, the reader is advised not to
place any undue reliance on such forward-looking statements. These forward-
looking statements speak only as of the date of publication of this document.
Biotie expressly disclaims any obligation to update any such forward-looking
statements in this document to reflect any change in its expectations with
regard thereto or any change in events, conditions or circumstances on which any
such statement is based, unless required by law or regulation.




[HUG#1926289]